BR112017025135A2 - processos para isolar um composto e para preparar um composto - Google Patents

processos para isolar um composto e para preparar um composto

Info

Publication number
BR112017025135A2
BR112017025135A2 BR112017025135A BR112017025135A BR112017025135A2 BR 112017025135 A2 BR112017025135 A2 BR 112017025135A2 BR 112017025135 A BR112017025135 A BR 112017025135A BR 112017025135 A BR112017025135 A BR 112017025135A BR 112017025135 A2 BR112017025135 A2 BR 112017025135A2
Authority
BR
Brazil
Prior art keywords
compound
formula
isolating
preparing
processes
Prior art date
Application number
BR112017025135A
Other languages
English (en)
Other versions
BR112017025135B1 (pt
Inventor
Meghani Premji
Lee Ford Rhonan
Original Assignee
Novassay Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novassay Sa filed Critical Novassay Sa
Publication of BR112017025135A2 publication Critical patent/BR112017025135A2/pt
Publication of BR112017025135B1 publication Critical patent/BR112017025135B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/02—Formation or introduction of functional groups containing nitrogen of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/08—Formation or introduction of functional groups containing nitrogen of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C07B63/02—Purification; Separation; Stabilisation; Use of additives by treatment giving rise to a chemical modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78—Separation; Purification; Stabilisation; Use of additives
    • C07C45/85—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to a chemical modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/613—Unsaturated compounds containing a keto groups being part of a ring polycyclic
    • C07C49/617—Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system
    • C07C49/623—Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system having two rings
    • C07C49/627—Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system having two rings the condensed ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

a presente invenção refere-se a um processo para isolar um composto de fórmula (2a) ou um sal ou solvato do mesmo, compreendendo a) fazer reagir uma mistura de diastereoisómeros de fórmulas (2a, 2b) com um composto aldeído heterocíclico básico e uma amina opticamente ativa na presença de um base; e b) separar o composto de fórmula (2a) do produto do passo a) por extração com ácido. o composto de fórmula (2a) pode ser produzido com um excesso enantiomérico de 98%. os compostos de fórmula (2a) são intermediários úteis num processo para preparar um derivado bicíclico de ¿-amino tetrazol de fórmula (i) que encontra utilidade no tratamento de dor neuropática e distúrbios do sistema nervoso central.
BR112017025135-3A 2015-05-27 2016-02-02 Processo para isolar um composto de fórmula 2a BR112017025135B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562167232P 2015-05-27 2015-05-27
US62/167,232 2015-05-27
PCT/EP2016/052176 WO2016146299A1 (en) 2015-05-27 2016-02-02 Separation of enantiomers of 3-ethylbicyclo[3.2.0]hept-3-en-6-one

Publications (2)

Publication Number Publication Date
BR112017025135A2 true BR112017025135A2 (pt) 2018-08-07
BR112017025135B1 BR112017025135B1 (pt) 2023-01-17

Family

ID=55404679

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017025135-3A BR112017025135B1 (pt) 2015-05-27 2016-02-02 Processo para isolar um composto de fórmula 2a

Country Status (11)

Country Link
US (1) US10150723B2 (pt)
EP (1) EP3303308B1 (pt)
JP (1) JP6775009B2 (pt)
KR (1) KR102598202B1 (pt)
CN (1) CN107667097B (pt)
AU (1) AU2016232606A1 (pt)
BR (1) BR112017025135B1 (pt)
CA (1) CA2986954C (pt)
RU (1) RU2734475C2 (pt)
WO (1) WO2016146299A1 (pt)
ZA (1) ZA201708769B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114264751B (zh) * 2021-12-28 2024-02-27 江苏威凯尔医药科技有限公司 一种高效液相色谱法分离米洛巴林中间体及其对映异构体的方法
CN115745764B (zh) * 2022-12-08 2024-03-12 重庆华森制药股份有限公司 一种米洛巴林中间体的制备方法
WO2024134671A1 (en) * 2022-12-21 2024-06-27 Bhisaj Pharmaceuticals Pvt Ltd Preparation of 3-ethylbicyclo[3.2.0]hept-3-en-6-one
CN116903468B (zh) * 2023-07-14 2024-01-26 山东新时代药业有限公司 一种米洛巴林中间体的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU147182A1 (ru) * 1961-07-18 1961-11-30 Е.С. Жданович Способ расщеплени синтетического рацемического альфа-окси-бета1-бета-диметил-гамма-бутиролактона
EP0074856A3 (en) * 1981-09-16 1984-02-01 Glaxo Group Limited Resolution of racemic bicycloheptenones
WO2010084798A1 (ja) * 2009-01-21 2010-07-29 第一三共株式会社 ３環性化合物
ES2635354T3 (es) * 2009-03-26 2017-10-03 Daiichi Sankyo Company, Limited Procedimiento de producción de un derivado de ácido gamma-amino bicíclico
BR112013031360B1 (pt) * 2011-06-08 2022-01-25 Daiichi Sankyo Company, Limited Método para produzir um composto
WO2012169475A1 (ja) 2011-06-08 2012-12-13 第一三共株式会社 クライゼン転位反応による二環性化合物の製造方法
BR112014014432B1 (pt) 2011-12-15 2022-03-29 Daiichi Sankyo Company, Limited Método para produzir um composto
ES2624314T3 (es) 2012-04-10 2017-07-13 Daiichi Sankyo Company, Limited Procedimiento de resolución óptica para compuestos bicíclicos usando enzima
JP2013245215A (ja) * 2012-05-29 2013-12-09 Daiichi Sankyo Co Ltd 不斉環化反応による光学活性二環性化合物の製造方法
EP3083572B1 (en) * 2013-12-18 2019-02-13 Novassay SA Gamma-aminobutyric acid (gaba) analogues for the treatment of pain and other disorders

Also Published As

Publication number Publication date
EP3303308B1 (en) 2019-10-09
KR20180036919A (ko) 2018-04-10
RU2017143338A (ru) 2019-06-27
US10150723B2 (en) 2018-12-11
WO2016146299A1 (en) 2016-09-22
JP2018517768A (ja) 2018-07-05
KR102598202B1 (ko) 2023-11-03
ZA201708769B (en) 2019-04-24
JP6775009B2 (ja) 2020-10-28
US20180134643A1 (en) 2018-05-17
CA2986954A1 (en) 2016-09-22
BR112017025135B1 (pt) 2023-01-17
RU2734475C2 (ru) 2020-10-16
RU2017143338A3 (pt) 2019-07-17
CA2986954C (en) 2023-06-27
CN107667097B (zh) 2021-02-12
EP3303308A1 (en) 2018-04-11
CN107667097A (zh) 2018-02-06
AU2016232606A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
BR112018075433A2 (pt) derivados de piperidinila, processo para sua preparação e composições farmacêuticas contendo-os
BR112017025135A2 (pt) processos para isolar um composto e para preparar um composto
UY32025A (es) Derivados sustituídos de la 6-cloro-2-hidroxi-3-(3,4-dioxo-ciclobut-1-enil-amino)-n-metoxi-n-metil-bencen-sulfonamida, solvatos, hidratos o sales farmacéuticamente aceptables de los mismos, proceso de preparación, composiciones y aplicaciones.
BR112017027831A2 (pt) derivados de hidroxiácido, um processo para sua preparação e composições farmacêuticas contendo-os
BR112012006031A2 (pt) processo para preparação de compostos azabicíclicos.
BR112016028273A8 (pt) derivados radiorrotulados de composto de 2-amino6-fluoro-n-[5-fluoro-piridin-3-il]-pirazol[1,5-a]pirimidin3-carboxamida úteis como inibidor de atr cinase, processo para preparação do referido composto, bem como diferentes formas sólidas do mesmo, uso destas, e composição farmacêutica
BR112015028452A2 (pt) agonistas do receptor somastatina subtipo 4 (sstr4)
BR112014018756A8 (pt) Processo para preparo de etil éster de ácido n-(4-ciclo-hexil-3-trifluorometil-benziloxi)-acetimídico
PA8642801A1 (es) Amidas sustituidas de acido tienopirrolcarboxilico, amidas del acido pirrolotiazolcarboxilico y analogos relacionadas como inhibidores de la caseina cinasa i
BR112014003079A2 (pt) derivado de 1,2,3,4-tetra-hidroquinolina útil para o tratamento de diabetes
BR112018073490A2 (pt) 6.7.beta-epóxidos esteroides como intermediários químicos
MX2018014164A (es) Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico.
AR084864A1 (es) Proceso de preparacion de girasa e inhibidores de topoisomerasa iv y compuestos intermediarios de dicho proceso
BR112016013618A8 (pt) derivados de maleimida como moduladores de série de reação de wnt, seus usos, composição farmacêutica e processo para a preparação dos mesmos
WO2016038628A3 (en) A process for preparing olodaterol and intermediates thereof
ATE551312T1 (de) Verfahren zur racematspaltung von zopiclon und zwischenprodukten
AR086848A1 (es) Procedimiento de sintesis y forma cristalina del hidrocloruro de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2-(1h)-il]propoxi}benzamida asi como las composiciones farmaceuticas que la contienen
AR061890A1 (es) Sal xinafoato del etil ester de la 1-[[5-(1s)-aminoetil)-2-[8-metoxi-2(trifluorometil)-5-quinolil]-4-oxazolil]carbonil]-(4r)-[(ciclopropil-carbonil)amino]-l-prolina.
BR112018013346A2 (pt) processo de preparação de 1,1,3-trioxo-1,2-benzotiazol-6-carboxamida
BR112015021151A2 (pt) processo para a preparação de (2s,5r)-ácido sulfúrico mono-{[(4-aminopiperidin-4-il)carbonil]-7-oxo-1,6-diazabiciclo[3.2.1]-oct-6-il} éster
BR112018016656A2 (pt) processo para preparar compostos do éster de aminotiol e seus sais
MX2022002568A (es) Proceso para preparar (r)-4-aminoindano y amidas correspondientes.
BRPI0416663A (pt) processos para a preparação de ftalimidas n-substituìdas
BR112018071742A2 (pt) processo para a preparação de compostos herbicidas de piridinilimidazolona
CO2020006788A2 (es) Método de producción de un compuesto intermedio para sintetizar un medicamento

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/02/2016, OBSERVADAS AS CONDICOES LEGAIS